Bajic et al., 2020 - Google Patents
Gut microbiota-derived propionate regulates the expression of Reg3 mucosal lectins and ameliorates experimental colitis in miceBajic et al., 2020
View PDF- Document ID
- 9819336138219921348
- Author
- Bajic D
- Niemann A
- Hillmer A
- Mejias-Luque R
- Bluemel S
- Docampo M
- Funk M
- Tonin E
- Boutros M
- Schnabl B
- Busch D
- Miki T
- Schmid R
- van den Brink M
- Gerhard M
- Stein-Thoeringer C
- Publication year
- Publication venue
- Journal of Crohn's and Colitis
External Links
Snippet
Abstract Background and Aims Regenerating islet-derived protein type 3 [Reg3] lectins are antimicrobial peptides at mucosal surfaces of the gut, whose expression is regulated by pathogenic gut microbes via interleukin-22-or Toll-like receptor signalling. In addition to …
- 230000014509 gene expression 0 title abstract description 82
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bajic et al. | Gut microbiota-derived propionate regulates the expression of Reg3 mucosal lectins and ameliorates experimental colitis in mice | |
| Busbee et al. | Indole-3-carbinol prevents colitis and associated microbial dysbiosis in an IL-22–dependent manner | |
| Morgantini et al. | Liver macrophages regulate systemic metabolism through non-inflammatory factors | |
| Yao et al. | MUC2 and related bacterial factors: Therapeutic targets for ulcerative colitis | |
| McFadden et al. | The role of curcumin in modulating colonic microbiota during colitis and colon cancer prevention | |
| Chen et al. | Skin and gut microbiome in psoriasis: gaining insight into the pathophysiology of it and finding novel therapeutic strategies | |
| Zhu et al. | 1, 25 (OH) 2D3 deficiency-induced gut microbial dysbiosis degrades the colonic mucus barrier in Cyp27b1 knockout mouse model | |
| Alrafas et al. | Resveratrol modulates the gut microbiota to prevent murine colitis development through induction of Tregs and suppression of Th17 cells | |
| Wang et al. | Intestinal autophagy links psychosocial stress with gut microbiota to promote inflammatory bowel disease | |
| Wang et al. | Gut microbiota-derived succinate aggravates acute lung injury after intestinal ischaemia/reperfusion in mice | |
| Cao et al. | Secondary bile acid‐induced dysbiosis promotes intestinal carcinogenesis | |
| Ma et al. | Dairy Propionibacterium freudenreichii ameliorates acute colitis by stimulating MUC2 expression in intestinal goblet cell in a DSS-induced colitis rat model | |
| Lei et al. | Disulfiram ameliorates nonalcoholic steatohepatitis by modulating the gut microbiota and bile acid metabolism | |
| Pérez-Matute et al. | Autologous fecal transplantation from a lean state potentiates caloric restriction effects on body weight and adiposity in obese mice | |
| Chassaing et al. | Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome | |
| Terasaki et al. | Alteration of fecal microbiota by fucoxanthin results in prevention of colorectal cancer in AOM/DSS mice | |
| Tremblay et al. | Bile acid administration elicits an intestinal antimicrobial program and reduces the bacterial burden in two mouse models of enteric infection | |
| Wei et al. | Fecal microbiota transplantation restores dysbiosis in patients with methicillin resistant Staphylococcus aureus enterocolitis | |
| Shukla et al. | Human defensin-5 blocks ethanol and colitis-induced dysbiosis, tight junction disruption and inflammation in mouse intestine | |
| Rodrigues et al. | Serum levels and mesenteric fat tissue expression of adiponectin and leptin in patients with Crohn's disease | |
| Furuhashi et al. | Dietary emulsifier polysorbate‐80‐induced small‐intestinal vulnerability to indomethacin‐induced lesions via dysbiosis | |
| Liu et al. | Gut microbiota‐derived nicotinamide mononucleotide alleviates acute pancreatitis by activating pancreatic SIRT3 signalling | |
| Cao et al. | Therapeutic mechanisms of berberine to improve the intestinal barrier function via modulating gut microbiota, TLR4/NF-κ B/MTORC pathway and autophagy in cats | |
| Li et al. | Dietary butyrate ameliorates metabolic health associated with selective proliferation of gut Lachnospiraceae bacterium 28-4 | |
| Liu et al. | The metabolite butyrate produced by gut microbiota inhibits cachexia-associated skeletal muscle atrophy by regulating intestinal barrier function and macrophage polarization |